Clinical Trial Search

Primary: Change in Apoptotic Indices Before and After Treatment — -2.99 Percentage of TUNEL positive cells

Primary: Antibody Concentrations Against Pneumococcal Serotypes During the Primary Phase of the Study — 1.54; 1.59; 1.37; 2.18 µg/mL

Primary: Change in Aberrant Behavior Checklist - Hyperactivity Subscale (ABC-H) Score — -5.3; -3.4 units on a scale

Primary: Overall Response Rate of RAD001 in Patients With Previously Untreated WM — 22 participants

Primary: Change in Automatic Postural Response (APR )Latency — 5.71; 4.58 milliseconds — p=0.51

Primary: Change From Baseline in Urine Glucose Excretion — 599.763; 43428.245; 81564.440; 89189.527 mg — p=<0.0001

Primary: The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72) — 80.8; 70.7; 77.9; 84.8 Percentage of participants — p=0.051

Primary: Area Under the Curve (0-t) of Plasma Metformin — 8672; 4774; 3842; 8075 ng*h/mL

Primary: Hypoglycaemic Events — 0.9; 1.8; 7.1; 2.4 percentage of participants

Primary: Change From Baseline in HbA1c After 12 Weeks of Treatment — 0.15; -0.09; -0.23; -0.56 percentage of HbA1c — p=0.0226

Primary: Pharmacodynamics - Prothrombin Time (PT), Baseline Value — 15.8 Seconds

Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless

Primary: Psychomotor Vigilance Task (PVT) Reaction Time — 279.1; 311.6; 333.8 Msec — p=0.47

Primary: Optimal Dose of RAD001 in Combination With Trastuzumab (Phase I) — 10 mg

Primary: Post Operative Pain — 2.56; 2.90 units on a scale